No Data
NetraMark Announces Change To Board Of Directors
NetraMark Appoints Dr. Panteli Theocharous as Fractional Chief Medical Officer
NetraMark To Open The Market At The Toronto Stock Exchange On May 5, 2026
NetraMark Positioned to Advance Psychedelic Clinical Trials Following U.S. Executive Order, Supported by Peer-Reviewed Research and Active Programs
Netramark Comments on U.S. Executive Order to Accelerate Treatments for Serious Mental Illness and Highlights the Need for Regulatory‐Grade Trial Design in Psychedelic Development
NetraMark Touts New Psychedelic Brain Research to Bolster AI-Driven Trial Design